HUTCHMED (China) Limited (HCM) is drawing attention after a series of clinical and regulatory milestones strengthened its late-stage pipeline. Shares closed higher on above-average volume, signaling strong momentum for the company. Recent progress includes positive Phase III results for sovleplenib in autoimmune hemolytic anemia, the launch of a pivotal trial for surufatinib in pancreatic cancer, and priority review status for savolitinib in gastric cancer. Together, these developments highlight HUTCHMED's expanding role in oncology and immunology, positioning the stock as one to watch in 2026.
Stock performance
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.